Importantly, patients with PD-L1 expression ≥ 1% on tumor or immune cells showed significantly improved outcomes, with an ORR of 40.0% and median PFS of 7.4 months, compared to PD-L1–negative patients. This evidence concerns the gene CD274 and neoplasm.